NOW · Investment summary · as of 29 July 2026
Priced slightly ahead of what the business has demonstrated
Business type: Compounder · mature and structurally stable
The operating path required by today's price is not achievable on the evidence.
At $115.76, NOW requires a 0% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 0%.
The value rests on an exit multiple of 12.5x and a terminal operating margin of 23%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Named cause: the product being sold is compressing the margin of the platform selling it, and the company has put that in writing.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | GAAP-profitable every quarter since 2019. Non-GAAP operating margin 29.7% -> 29.4% -> 31.5% guided; five-year range approx 25-32%. Revenue growth 21-24% for six consecutive years, no exogenous cycle. |
| What do we forecast? | Revenue growth of 0% demonstrated; a terminal operating margin of 23%; an exit multiple of 12.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -13.2 percentage points. |
| What is it worth? | Twelve-month target $166.00, +43% from the struck price. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Not determined — no falsifiable operating conditions are on file for this name, so the thesis cannot be reduced to a small number of testable claims
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 28 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
Named cause: the product being sold is compressing the margin of the platform selling it, and the company has put that in writing. FY2026 gross-margin guidance is explicitly reduced for *"an acceleration of customer AI adoption"* and hyperscaler usage. Ex-amortisation subscription gross margin fell ~2.1pp YoY.
Not determined — no falsifiable invalidation conditions are on file, so this position cannot be risk-monitored
On approach to the $166.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Named cause: the product being sold is compressing the margin of the platform selling it, and the company has put that in writing. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -13.2 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: named cause: the product being sold is compressing the margin of the platform selling it, and the company has put that in writing. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $94.94, which forces an immediate review.